HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Computer model of the interaction of human TFPI-2 Kunitz-type serine protease inhibitor with human plasmin

Abstract : Computer model of the interaction of human TFPI-2 Kunitz-type serine protease inhibitor with human plasmin Dear Sir, Tissue factor pathway inhibitor-2 (TFPI-2) is a 32-kDa serine proteinase inhibitor that strongly inhibits trypsin, plasmin, factor XIa and plasma kallikrein [1], and is mainly associated with extracellular matrices [2]. By inhibiting plasmin, TFPI-2 thus efficiently decreases activation of several metalloproteinases [2] and reduces tumor invasion and metastasis [3,4]. In addition, TFPI-2 can also regulate plasmin in atherosclerotic plaques by modulating extracel-lular proteolytic mechanisms [5]. TFPI-2, which is a member of the Kunitz-type serine proteinase inhibitor family, consists of three tandemly repeated Kunitz-type domains, the first of which (K1) exhibits similarities in amino acid sequence to TFPI-1 and bovine pancreatic trypsin inhibitor (BPTI) (45% and 40%, respectively). The inhibition of serine proteinases by Kunitz-type inhibitors involves their binding to K1 and P1 residue that interacts with the proteinase pocket previously identified to be an arginine or a lysine residue [6-9]. Using site-directed mutagenesis experiments, Kamei et al. [10] reported that a TFPI-2 mutant with glutamine substituted for arginine lost its inhibitory activity towards trypsin and plasmin. Several structures showing the interaction of one serine proteinase with a Kunitz-type inhibitor, i.e. thrombin with BPTI [6], factor Xa/VIIa with TFPI-1 [7,8] and alpha-chymotrypsin with BPTI [9], have been determined crystallographically. However , TFPI-2 structure and plasmin complexed with a Kunitz-type inhibitor have not to date been described. This report is the first to address the structural basis for molecular recognition of plasmin by the K1 domain of TFPI-2 (TFPI-2/K1). The 3D models of TFPI-2/K1 was built using the automatic comparative modeling server swissPDB (http:// www.expasy.org). The structure of TFPI-1/K2 (44% identity with TFPI-2/K1 in 55 residues) was used as template to determine TFPI-2/K1. The resulting model was further energy-minimized using the steepest descent algorithm (SYBYL 6.9, Tripos, http://www.tripos.com), the atoms of the backbone being constrained during this step, and un-constrained using the conjugate gradient algorithm until the maximum derivative was < 0.1 kcal/mol/A ˚. After checking the stereochemical quality (WHATIF, http://www.cmbi. kun.nl/), all parameters were good for ensemble structure. The TFPI-2/K1 model and plasmin (coordinates extracted from the PDB file 1 bml) were superimposed on the Ca atoms of the TFPI-1/trypsin complex (coordinates extracted from the PDB file 1tfx). Finally, the few atoms that overlapped at the complex interface were relieved by energy minimization. The electrostatic potentials of TFPI-2/K1 and plasmin were calculated with swissPDB viewer 3.7b software and using formal charges at pH 7.4 (arginine, lysine, N-terminus, + 1; glutamate, aspartate and the C-terminus, À 1; and histidine, neutral), ionic strength in the aqueous environment of 0.15 M and dielectric constant of 80. The three-dimensional structure of TFPI-2/K1 exhibited the typical Kunitz-type proteinase inhibitor folding, i.e. a double stranded anti-parallel h-sheet from Arg20 to Phe33, and an a-helix from Trp48 to Ala54. The core of the domain, comprising the secondary structure elements and the three disulfide bonds, was highly conserved. TFPI-2/K1 exhibited the same overall fold as BPTI [6] and TFPI-1/K2 [7], with rms deviations (root-mean-square) for all 55 Ca atom positions of 0.70 and 1.09 A ˚ , respectively. These values are in agreement with the 40% identity with BPTI and 45% identity with TFPI-1/K2. The binding loop of TFPI-2/K1 (Leu19-Tyr33) was in direct contact with the active site of plasmin involving the characteristic main-main conforma-tional and intermolecular hydrogen bond interactions of canonical binding proteinase inhibitors [7-9]. Indeed, as shown in Table 1, TFPI-2/K1 residues positioned close to the active site of plasmin (PV2, PV1, P1 and P3 residues) were involved in hydrogen bonds. As compared with the TFPI-1/trypsin complex [7], two additional hydrogen bonds were found at the interface between TFPI-2/K1 and plasmin, probably improving the complementarity between the two molecules. The side-chain of TFPI-2 P1 residues (Arg15) extended into the plasmin-specific pocket, with its guanidi-nium group forming a salt bridge with the carboxylate group 0049-3848/$-see front matter D
Document type :
Journal articles
Complete list of metadata

Cited literature [10 references]  Display  Hide  Download

Contributor : Florent Hube Connect in order to contact the contributor
Submitted on : Tuesday, May 21, 2019 - 1:49:03 PM
Last modification on : Tuesday, March 15, 2022 - 3:52:02 PM

Links full text




F Hubé, Pascale Reverdiau, S Iochmann, Y. Gruel. Computer model of the interaction of human TFPI-2 Kunitz-type serine protease inhibitor with human plasmin. Thrombosis Research, Elsevier, 2003, 111 (3), pp.197-198. ⟨10.1016/j.thromres.2003.09.021⟩. ⟨hal-02127392⟩



Record views